Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Warning issued over eye exposure to ear drops
EMA said veterinary surgeons should advise pet owners to take care when applying Osurnia.
Reports of eye injuries in people and pets after accidental exposure 

The European Medicines Agency has issued a warning about accidental exposure to Osurnia ear gel for dogs, after a number of pets and owners suffered eye injuries.

Injuries reported in people include two cases of corneal ulcers, as well as complaints of eye irritation, conjunctivitis, redness, during, stinging and itchiness. In dogs, there were reports of corneal ulcers, squinting, impaired vision, conjunctivitis, redness and swelling around the eye.

Eye exposure in humans largely occurred when the dog shook its head during or just after the medication was applied to the ear.

Veterinary professionals will be informed about this issue in writing and are being encouraged to report any suspected side effects to the relevant national authority, or the manufacturer of Osurnia, Elanco Europe Ltd.

EMA said veterinary surgeons should advise pet owners to take care when applying Osurnia, taking appropriate measures to ensure the product does not contact the eyes of people or dogs. This includes restraining the animal’s head while the medicine is applied.

If accidental exposure does occur, rinse the eyes thoroughly with water for 10-15 minutes and seek medical care.

Pet owners should also monitor dogs treated with the product and contact their vet if they notice any side effects, particularly those affecting the eyes.

EMA says it will continue to monitor the safety of the medicine and will take regulatory action as appropriate.

Become a member or log in to add this story to your CPD history

Building Great Workplaces webinars return

News Story 1
 BVA has announced a new series of its Building Great Workplaces lunchtime webinars.

Launching from 16 July, the sessions will explore patient safety, motivation, client communication and more.

Its first webinar, exploring neurodiversity in the workplace, will take place at 1pm on Thursday, 16 July. It will feature guest speakers from The Vet Project, a group which supports neurodiversity in veterinary environments.

The following three webinars take place in September, October and November.

Booking is open on the BVA website 

Click here for more...
News Shorts
New form for online veterinary medicines retailers

The Veterinary Medicines Directorate (VMD) has produced a new online form for retailers wishing to sell veterinary medicines on the internet.

The form replace the previous Word version and is part of the VMD's ongoing commitment to digitise its processes. Anyone retailing prescription medicines online, including POM-V, POM-VPS and NFA-VPS categories, is lawfully required to register with the VMD before trading.

The change only applies to new applicants. Retailers already listed on the VMD's Register of Online Retailers or registered under the Accredited Internet Retailer Scheme (AIRS) do not need to do anything.